Organogenesis Holdings Inc. is a regenerative medicine and tissue innovations company that develops manufactures and sells products for the advanced wound care surgical and sports medicine markets. The company’s mission is to provide an integrated portfolio of healing and tissue solutions that improve lives while lowering the overall cost of health care. Its products are designed to treat chronic and acute wounds as well as tendon ligament injuries and osteoarthritis…
Organogenesis Holdings Inc. is a regenerative medicine and tissue innovations company that develops manufactures and sells products for the advanced wound care surgical and sports medicine markets. The company’s mission is to provide an integrated portfolio of healing and tissue solutions that improve lives while lowering the overall cost of health care. Its products are designed to treat chronic and acute wounds as well as tendon ligament injuries and osteoarthritis symptoms. Several of its marketed products have received premarket approval or 510k clearance from the United States Food and Drug Administration. Organogenesis serves a diverse set of health care customers including hospitals wound care centers government facilities ambulatory surgery centers and physician offices.
Organogenesis generates revenue primarily from the sale of its regenerative medicine products such as Apligraf for venous leg ulcers and diabetic foot ulcers Dermagraft for diabetic foot ulcers though manufacturing is currently suspended PuraPly AM as an antimicrobial barrier for various wound types CYGNUS Dual as a dual layered amniotic membrane VIA Matrix Affinity Novachor and NuShield placental allografts used as protective barriers and extracellular matrix scaffolds. The company also earns revenue from licensing agreements such as the arrangement with Vivex Biologics for the CYGNUS Dual and VIA products and from the sale of PuraForce reinforcement matrix and other surgical products. Additionally Organogenesis receives upfront and milestone payments under its collaboration agreements and pays royalties on net sales of licensed products as defined in those contracts. Sales are made to health care providers in the United States and through distributors in select international markets including Switzerland Saudi Arabia and Kuwait.
The company operates through the following segments: Advanced Wound Care and Surgical & Sports Medicine. Each segment encompasses distinct product families that address specific clinical needs while sharing common manufacturing and regulatory capabilities.
• Advanced Wound Care includes Apligraf a bioengineered bilayered skin substitute with PMA approval for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a dermal scaffold that supports diabetic foot ulcer healing though its manufacturing is temporarily suspended while the company prepares to transfer production to its newly leased facility in Smithfield Rhode Island. PuraPly AM functions as an antimicrobial barrier made from porcine collagen combined with polyhexamethylene biguanide to manage bioburden across a range of wound types including partial and full thickness wounds pressure ulcers venous ulcers diabetic ulcers and surgical wounds. CYGNUS Dual is a dual layered amniotic membrane that can be stored at room temperature and provides a protective extracellular matrix scaffold for chronic and acute wounds. VIA Matrix Affinity Novachor and NuShield are placental allografts that serve as protective barriers and extracellular matrix scaffolds for various wound sizes and types.
• Surgical & Sports Medicine features NuShield a dehydrated placental allograft used as a surgical barrier and extracellular matrix scaffold to support soft tissue repair. PuraForce is a bioengineered porcine collagen matrix designed for soft tissue reinforcement in procedures such as tendon and ligament repair. Affinity and Novachor are placental allografts that are marketed for acute surgical wounds and for use as protective barriers in the operating room. PuraPly AM and PuraPly SX provide antimicrobial barrier function for open wounds encountered during surgery while PuraPly MZ offers a micronized particulate version that can be applied as a powder or gel. The segment also includes the investigational product ReNu a cryopreserved suspension derived from human amniotic fluid being evaluated in phase three clinical trials for symptomatic knee osteoarthritis with plans to study hip osteoarthritis.
Organogenesis holds a strong position in the regenerative medicine industry due to its broad portfolio of FDA cleared and approved products its in house clinical and reimbursement support and its established relationships with group purchasing organizations. Competitors include other developers of skin substitutes placental based therapies and orthobiologics but the company differentiates itself through the combination of PMA approved 510k cleared products and proven clinical evidence from large trials. The company’s focus on products that address large and growing markets driven by aging populations and rising diabetes and obesity rates further supports its competitive stance. Organogenesis also leverages its proprietary processing methods such as AlloFresh and LayerLoc to maintain the biological activity of its tissue based products. These manufacturing advantages help ensure product consistency and reduce reliance on external suppliers.
The company serves hospitals wound care centers government facilities ambulatory surgery centers and physician offices across the United States. In addition Organogenesis distributes select products through independent agents in Switzerland Saudi Arabia and Kuwait and is evaluating regulatory pathways for potential expansion in the European Union. These customers rely on Medicare Medicaid and private payer reimbursement for the use of its advanced wound care and surgical products. Organogenesis provides in house reimbursement support medical technical assistance and field based medical science liaisons to help clinicians navigate coverage and billing requirements. By maintaining direct relationships with health care providers the company aims to improve product adoption and ensure consistent supply of its regenerative therapies.
Sector:HealthcareSector rationaleOrganogenesis develops, manufactures, and sells regenerative medicine products, such as Apligraf and PuraPly AM, used for advanced wound care and surgical applications. Its customers are hospitals, wound care centers, and physician offices, and its revenue is derived from the sale of medical devices and biologics.Industries:Medical DevicesHealthcarePrimaryOrganogenesis designs and manufactures therapeutic medical devices and regenerative medicine products, such as PuraForce reinforcement matrix for tendon and ligament repair and NuShield placental allografts used as surgical barriers. These products are sold to hospitals, ambulatory surgery centers, and physician offices for clinical treatment.BiotechnologyHealthcareSecondaryThe company develops and commercializes therapies derived from biological science, specifically bioengineered skin substitutes like Apligraf and Dermagraft, as well as placental allografts and porcine collagen matrices.Classified using BQ-MICSCIK: 0001661181
Investment Thesis
▲ Bull case
Despite the reported 58% decline in net revenue in the Q1 FY26 the company’s core brands excluding Apligraf fell only about 22% indicating that Organogenesis is gaining share in a contracting market. Management noted that unit volume outperformed the industry wide decline which suggests that clinicians continue to prefer its products when they can obtain them. This relative strength is expected to translate into additional share gains as reimbursement confusion begins to clear later in the year. The firm’s long standing position as a leader with a broad portfolio across FDA categories provides a platform to capture more of the remaining demand.
A significant near term catalyst is the completion of the Biologics License Application for ReNu which targets symptomatic knee osteoarthritis a condition affecting more than 30,000,000 Americans. The submission includes nonclinical chemistry manufacturing and control modules and now awaits FDA review. If approved ReNu would offer a nonsurgical biologic option for patients lacking effective therapies creating a new revenue stream outside the wound care segment. Success here could diversify the business model and reduce dependence on reimbursement volatile skin substitute markets.
The recent randomized controlled trial of PuraPly AM plus standard of care for diabetic foot ulcers met its primary endpoint showing statistically significant wound closure at 12 weeks with a p value below 0.0477. This robust evidence reinforces the clinical efficacy of the antimicrobial technology and supports its inclusion in future coverage policies. Positive trial results are likely to strengthen payer conversations and may accelerate reimbursement restoration for this product line. Enhanced coverage would drive higher utilization and revenue growth for the Advanced Wound Care franchise.
Organogenesis entered FY26 with a strong liquidity position of $92,100,000 in cash and cash equivalents and no outstanding debt while retaining access to up to $75,000,000 under its revolving facility. The March restructuring removed 88 positions and closed the St Petersburg Florida facility generating an estimated $14,000,000 of annualized cost savings. These actions combined with a planned 25% year over year reduction in operating expenses excluding cost of goods sold should improve cash flow and support a return to positive adjusted EBITDA in the second half of the year. The balance sheet flexibility gives the company time to navigate the current reimbursement headwinds while executing its growth initiatives.
Despite the reported 58% decline in net revenue in the Q1 FY26 the company’s core brands excluding Apligraf fell only about 22% indicating that Organogenesis is gaining share in a contracting market. Management noted that unit volume outperformed the industry wide decline which suggests that clinicians continue to prefer its products when they can obtain them. This relative strength is expected to translate into additional share gains as reimbursement confusion begins to clear later in the year. The firm’s long standing position as a leader with a broad portfolio across FDA categories provides a platform to capture more of the remaining demand.
A significant near term catalyst is the completion of the Biologics License Application for ReNu which targets symptomatic knee osteoarthritis a condition affecting more than 30,000,000 Americans. The submission includes nonclinical chemistry manufacturing and control modules and now awaits FDA review. If approved ReNu would offer a nonsurgical biologic option for patients lacking effective therapies creating a new revenue stream outside the wound care segment. Success here could diversify the business model and reduce dependence on reimbursement volatile skin substitute markets.
The recent randomized controlled trial of PuraPly AM plus standard of care for diabetic foot ulcers met its primary endpoint showing statistically significant wound closure at 12 weeks with a p value below 0.0477. This robust evidence reinforces the clinical efficacy of the antimicrobial technology and supports its inclusion in future coverage policies. Positive trial results are likely to strengthen payer conversations and may accelerate reimbursement restoration for this product line. Enhanced coverage would drive higher utilization and revenue growth for the Advanced Wound Care franchise.
Organogenesis entered FY26 with a strong liquidity position of $92,100,000 in cash and cash equivalents and no outstanding debt while retaining access to up to $75,000,000 under its revolving facility. The March restructuring removed 88 positions and closed the St Petersburg Florida facility generating an estimated $14,000,000 of annualized cost savings. These actions combined with a planned 25% year over year reduction in operating expenses excluding cost of goods sold should improve cash flow and support a return to positive adjusted EBITDA in the second half of the year. The balance sheet flexibility gives the company time to navigate the current reimbursement headwinds while executing its growth initiatives.
The most pressing risk is the continued uncertainty surrounding CMS commentary on product wastage issued on December 30 which has created clinician confusion and disrupted utilization of PMA approved skin substitutes such as Apligraf. Management admitted they have no clear timeline for when the agency will provide clarification or exempt PMA products from the wastage rule. Without such resolution the market may remain depressed for longer than anticipated limiting any sequential revenue improvement. Prolonged confusion could also push providers to abandon skin substitutes altogether further shrinking the addressable market.
Organogenesis remains heavily reliant on its PMA approved portfolio especially Apligraf which accounts for a meaningful portion of Advanced Wound Care sales. Any adverse coverage decision or continued billing complexity directly threatens the core revenue base. Competitors that focus on larger sized amniotic products may exploit the current policy environment gaining share at the expense of the company’s offerings. This concentration risk makes the business vulnerable to regulatory shifts that are outside management’s control.
Although the company reported $92,100,000 of cash the first quarter generated an operating loss of $68,900,000 and an adjusted net loss of $43,700,000 reflecting substantial cash burn. The restructuring is expected to save $14,000,000 annually but the full impact will not be felt until the second half of the year and there is a risk that savings fall short of expectations. Inventory write downs related to excess and obsolete stock further pressured gross margin dropping to 29% GAAP and 41% non GAAP in the quarter. Continued losses could erode the cash buffer and may necessitate additional financing or dilution if recovery stalls.
The updated full year 2026 revenue guidance of $270,000,000 to $310,000,000 implies a decline of 45% to 52% year over year and assumes a more measured recovery in clinician confidence and market conditions. If the sequential improvement anticipated in the second half fails to materialize due to lingering reimbursement obstacles or macroeconomic pressures the company could miss both revenue and profitability targets. Missing guidance may lead to negative investor sentiment and could affect the company’s ability to fund future pipeline investments such as ReNu and next generation wound care products. Such a shortfall could also increase pressure on management to pursue additional cost cutting measures that might impede long term growth initiatives.
The most pressing risk is the continued uncertainty surrounding CMS commentary on product wastage issued on December 30 which has created clinician confusion and disrupted utilization of PMA approved skin substitutes such as Apligraf. Management admitted they have no clear timeline for when the agency will provide clarification or exempt PMA products from the wastage rule. Without such resolution the market may remain depressed for longer than anticipated limiting any sequential revenue improvement. Prolonged confusion could also push providers to abandon skin substitutes altogether further shrinking the addressable market.
Organogenesis remains heavily reliant on its PMA approved portfolio especially Apligraf which accounts for a meaningful portion of Advanced Wound Care sales. Any adverse coverage decision or continued billing complexity directly threatens the core revenue base. Competitors that focus on larger sized amniotic products may exploit the current policy environment gaining share at the expense of the company’s offerings. This concentration risk makes the business vulnerable to regulatory shifts that are outside management’s control.
Although the company reported $92,100,000 of cash the first quarter generated an operating loss of $68,900,000 and an adjusted net loss of $43,700,000 reflecting substantial cash burn. The restructuring is expected to save $14,000,000 annually but the full impact will not be felt until the second half of the year and there is a risk that savings fall short of expectations. Inventory write downs related to excess and obsolete stock further pressured gross margin dropping to 29% GAAP and 41% non GAAP in the quarter. Continued losses could erode the cash buffer and may necessitate additional financing or dilution if recovery stalls.
The updated full year 2026 revenue guidance of $270,000,000 to $310,000,000 implies a decline of 45% to 52% year over year and assumes a more measured recovery in clinician confidence and market conditions. If the sequential improvement anticipated in the second half fails to materialize due to lingering reimbursement obstacles or macroeconomic pressures the company could miss both revenue and profitability targets. Missing guidance may lead to negative investor sentiment and could affect the company’s ability to fund future pipeline investments such as ReNu and next generation wound care products. Such a shortfall could also increase pressure on management to pursue additional cost cutting measures that might impede long term growth initiatives.